Table 1 Characteristics of the study population
From: Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection
|  | BSI group (n = 11) | No BSI group (n = 17) | p value |
|---|---|---|---|
Age (years) | 59 [46–61] | 54.5 [45–60] | 0.80 |
Sex (male) | 7 (64 %, 35–85) | 13 (76 %, 53–90) | 0.75 |
Body mass index | 24 [22–28] | 25 [24–28] | 0.90 |
Antibiotic prophylaxis | 9 (82 %, 52–95) | 15 (88 %, 65–97) | 0.99 |
Penicillin V | 8 (72 %, 49–92) | 6 (35 %, 17–59) | 0.12 |
Cotrimoxazole | 7 (63 %, 36–85) | 12 (70 %, 47–87) | 0.99 |
ICU admission | 1 (9.0 %, 1.6–37.7) | 2 (11.8 %, 2.0–37.8) | 0.99 |
Days of neutropenia | 9.0 [8.5-10.0] | 10 [9–11] | 0.27 |
Previous chemotherapy (months) | 4.0 [3–7.5] | 4 [3–5] | 0.44 |
Previous antibiotic treatment (months) | 4.0 [2–5] | 4 [3–5] | 0.66 |
Other comorbidities, hypertension | 4 (36.4 % 12.7–68.4) | 2 (11.8 %, 2.0–37.8) | 0.28 |
Diffuse large B-cell lymphoma | 9 (81.8 %, 47.8–96.8) | 10 (58.9 %, 36.0–78.4) | 0.39 |
Follicular lymphoma | 0 (0.0 %, 0.0–25.8) | 2 (11.8 %, 2.0–37.8) | 0.67 |
Burkitt lymphoma | 0 (0.0 %, 0.0–25.8) | 1 (5.9 %, 1.0–27.0) | 0.99 |
Mantle cell lymphoma | 2 (57.1 %, 25.0–84.2) | 3 (17.6 %, 6.2–41.0) | 0.39 |
Anaplastic large cell lymphoma | 0 (0.0 %, 0.0–25.8) | 1 (5.9 %, 1.0–27.0) | 0.99 |